Lexaria Bioscience Corp. (LEXX)

NASDAQ: LEXX · IEX Real-Time Price · USD
2.84
+0.01 (0.35%)
At close: Aug 8, 2022 10:42 AM
2.87
+0.04 (1.23%)
After-hours: Aug 8, 2022 4:41 PM EDT
0.35%
Market Cap 16.87M
Revenue (ttm) 175,268
Net Income (ttm) -6.98M
Shares Out 5.95M
EPS (ttm) -1.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,538
Open 2.75
Previous Close 2.83
Day's Range 2.75 - 2.87
52-Week Range 1.85 - 7.20
Beta 1.22
Analysts Buy
Price Target 13.01 (+358.9%)
Earnings Date Jul 21, 2022

About LEXX

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for oral... [Read more...]

Industry Biotechnology
Founded 2004
Employees 6
Stock Exchange NASDAQ
Ticker Symbol LEXX
Full Company Profile

Financial Performance

In 2021, LEXX's revenue was $722,738, an increase of 129.59% compared to the previous year's $314,793. Losses were -$4.19 million, 2.49% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for LEXX stock is "Buy." The 12-month stock price forecast is 13.01, which is an increase of 358.91% from the latest price.

Price Target
$13.01
(358.91% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events

KELOWNA, BC / ACCESSWIRE / July 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that do...

Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Pro...

KELOWNA, BC / ACCESSWIRE / July 26, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that it...

Why Shares Of Lexaria Biosciences Are Trading Higher

Lexaria Bioscience Corp. (NASDAQ: LEXX) shares are trading higher after the company announced manufacturing and license agreements with BevNology. The first agreement is a manufacturing operating agreem...

Lexaria Grants License to AnodGen Bioceuticals

DehydraTECH Pharmaceutical License Issued for the European, Australian and New Zealand markets Lexaria to receive royalty revenue from DehydraTECH product sales KELOWNA, BC / ACCESSWIRE / June 8, 2022 /...

Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA

KELOWNA, BC / ACCESSWIRE / June 6, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has s...

Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the...

Minimum payments due to Lexaria of US$4,527,500 over the first five years to retain exclusivity Lexaria to receive royalty revenue from DehydraTECH product sales KELOWNA, BC / ACCESSWIRE / June 2, 2022 ...

Lexaria Grants License to Valcon Medical for the European Market

Contract Manufacturing Organization first in Europe to License DehydraTECH Lexaria will receive milestone fees and royalty payments from product sales KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria B...

Lexaria Announces 2022 Annual Meeting Results

KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 20...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.”

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space

NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trust...

Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs

Lexaria Bioscience Corp (NASDAQ: LEXX) is receiving its first-ever patent for DehydraTECH technology in the enhanced delivery of antiviral drugs. Lexaria has received notification from the United States...

Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs

25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" ...

Lexaria Commences Multi-Week Human Clinical Hypertension Study

HYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefits This study is designed to enhance Lexaria's probabilities of success with its expe...

Why Is Lexaria Bioscience (LEXX) Stock Up Today?

Today, investors in Lexaria Bioscience and LEXX stock are seeing impressive gains as investors price a key catalyst into shares. The post Why Is Lexaria Bioscience (LEXX) Stock Up Today?

Why Lexaria Shares Are Rising Today

Lexaria Bioscience Corp (NASDAQ: LEXX) said that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 are complete, assessing a single 300mg dose of DehydraTECH-process...

Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results

Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug A...

Lexaria Provides Update on Human Nicotine Study NIC-H22-1

Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 / Lexaria B...

Lexaria Begins New Nicotine Formulation Creation and Evaluation Program

KELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered new...

Lexaria Begins DehydraTECH-CBD Epilepsy Research Program

Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; DehydraTECH-CBD test articles have been delivered to the laboratory ready to c...

Lexaria Granted Important New Oral Nicotine Patent

Newest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global inno...

Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study

DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexa...

Lexaria Provides Annual Letter From the CEO

KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an a...

Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2

"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2 " KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" o...

Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4

• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug ...

Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.

KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has ente...